Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?

Nature Reviews Neurology, Published online: 10 January 2023; doi:10.1038/s41582-022-00767-xFindings from a worldwide cohort of cognitively unimpaired individuals demonstrate that the presence of two canonical Alzheimer disease biomarkers — amyloid and tau — can reliably predict progression to mild cognitive impairment in the short-term. The results support the use of these biomarkers to diagnose preclinical Alzheimer disease in a clinical setting.

Source: Nature Reviews Neurology - January 10, 2023 Category: Neurology Authors: Marwan N. Sabbagh Boris DeCourt Source Type: research